Salbutamol metered-dose inhalation - AstraZeneca
Alternative Names: Albuterol sulfate metered dose inhalation- Pearl Therapeutics; AS MDI; PT 007Latest Information Update: 01 Jul 2025
At a glance
- Originator Pearl Therapeutics
- Developer AstraZeneca
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Phenols; Small molecules; Tocolytics
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma
Most Recent Events
- 04 Jun 2025 AstraZeneca completes a phase-III MITCHELL clinical trial in Asthma in USA (Inhalation) (NCT06644924)
- 10 Feb 2025 AstraZeneca initiates a phase-III MITCHELL clinical trial in Asthma in USA (Inhalation) (NCT06644924)
- 17 Jan 2025 No development reported - Phase-II for Asthma (In adolescents, In adults) in USA (Inhalation)